Anti-CD47 combats chronic lymphocytic leukemia (November 1999)
B-cell chronic lymphocytic leukemia (B-CLL) is
the most common hematological cancer in Western Countries. Despite the development of new
drugs, CLL is incurable. However, Marika Sarfati and colleagues of the Centre de
Recherche, Quebec, reported in November 1999 issue of Nature Medicine that an antibody
against the newly discovered thrombospondin receptor CD47, can destroy B-CLL cells,
opening new therapeutic strategies against this cancer.
Holisticonline.com is developed and maintained
by ICBS, Inc.